Lamivudine, Abacavir and Dolutegravir

Therapeutic indications

Lamivudine, Abacavir and Dolutegravir is indicated for:

Human immunodeficiency virus infection

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Dolutegravir/abacavir/lamivudine combination is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected children weighing at least 14 kg.

Before initiating treatment with abacavir-containing products, screening for carriage of the HLAB*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighing 14-20 kg, 25 mg/300 mg/150 mg once daily, for patients weighing 20-25 kg 30 mg/360 mg/180 mg once daily and for patients weighing >25 kg, 50 mg/600 mg/300 mg of dolutegravir/abacavir/lamivudine once daily

50 mg of dolutegravir, 600 mg of abacavir and 300 mg of lamivudine once daily

Contraindications

Lamivudine, Abacavir and Dolutegravir is contraindicated in the following cases:

Lactation

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.